CN106924307A - Application of the radix bupleuri in the medicine for preparing treatment virus B hepatitis - Google Patents
Application of the radix bupleuri in the medicine for preparing treatment virus B hepatitis Download PDFInfo
- Publication number
- CN106924307A CN106924307A CN201511007901.4A CN201511007901A CN106924307A CN 106924307 A CN106924307 A CN 106924307A CN 201511007901 A CN201511007901 A CN 201511007901A CN 106924307 A CN106924307 A CN 106924307A
- Authority
- CN
- China
- Prior art keywords
- medicine
- hepatitis
- radix bupleuri
- chinese medicine
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses application of the radix bupleuri in the medicine for preparing treatment virus B hepatitis.Described radix bupleuri is extracted as solvent with water, ethanol or carbon dioxide and is made bupleurum extract.Radix bupleuri or bupleurum extract are prepared into any formulation such as tablet, capsule, granule, the pill of art of pharmacy according to common process.It is applied to prepare the medicine for the treatment of virus B hepatitis, is, with radix bupleuri as raw material, to be prepared into the medicine suitable for clinically using.Described radix bupleuri can significantly reduce DHBV-DNA titres, HBsAg levels and AST, ALT activity in hepatitis B model duck serum, and the 7th day after drug withdrawal, have no rebound phenomenon；Denaturation and necrosis and the inflammatory cell infiltration of liver cell can also be reduced.Prompting said composition has the effect of significant anti-DHB, therefore prompting said preparation has the value of clinical practice.The medicine formulation science that the medicine is used to treat virus B hepatitis is reasonable.
Description
Technical field
The present invention relates to novel clinical use of the radix bupleuri in the medicine for preparing treatment virus B hepatitis, belong to pharmacy skill
Art field.
Background technology
Since hepatitis type B virus (HePatitis B virus, HBV) finds from the eighties of last century sixties, exist always
The mankind are annoying in global range, although oneself carries out Immunization programme through extensive for many countries, but is reported according to the World Health Organization (WHO)
Accuse, in global 6,000,000,000 populations, 1/2 people lives in HBV Endemic Areas high, and about 2,000,000,000 people have been proved to HBV infection, 3 ~ 400,000,000 people
It is HBV chronic infections, wherein 25% ~ 40% most dies from cirrhosis and liver cancer at last.In 10 disease causes of the death before the whole world, B-mode disease
Virus hepatitis account for the 7th, every year because virus B hepatitis died is about 750,000 (http://www.who.lnt/csr/
disease/hepatitis/).Compared with other countries in the world, China is the district occurred frequently of hepatitis B, the crowd for having 60%
Virus B hepatitis virus was infected, wherein virus B hepatitis virus carrier accounts for total population more than 1.2 hundred million
10%, Patients With Chronic Hepatitis B about 30,000,000 has 300,000 people to die from what virus B hepatitis virus caused every year
Hepatopathy or relevant disease, and annual virus B hepatitis neopathy number there are about 500,000, just have one in every four epidemic victims
Position virus B hepatitis patient (Zhang Xuqing turns round and look at Changhai, 2001), therefore carry out the basis to Type B viral hepatitis and application
Research has turned into the most important thing.
Chronic hepatitis B belongs to the category of the cards such as motherland medical science yellow subcutaneous ulcer, hypochondriac pain, vomiting, ruffian card.Its diseased region is more in liver
Courage taste, evil epidemic disease poison when mostly experiencing, burnt in strongly fragrant resistance, transporting and transforming function of the spleen and stomach is not normal；Or eating and drinking without temperance, it to be addicted to drink excessively, impairing the spleen and stomach is wet
The strongly fragrant resistance liver and gall of heat；Or feelings will is hindered, angry impariment of the liver etc. triggers.Although the etiology and pathology of chronic hepatitis B changes various, gas
The empty tired card of blood is its common, multiple clinical onset type.Taste are the foundation of acquired constitution, source of generating QI and blood, the sick long or mistake rules for the treatment of
Taste are damaged, and the middle deficiency of vital energy is weak, the transportation capabilities dereliction of duty of spleen, not normal, the train of thought stasis of middle burnt mechanism of qi mediation；Spleen-Qi Deficiency, powerless transporting
Essence of water and grain makes moist four limbs then lassitude of the limbs and weakness；Taste are empty, and digesting food is had no right, lost the appetite, stomach Qi upward reversal then n and V.
Qi as the commander of blood, blood circulation depending on qi flow, blood stored in the liver, main catharsis, courage is fu-viscera with decisive character, is stored and catharsis bile, and liver and gall are mutually coordinated.If spleen
The deficiency of vital energy can not unite blood, liver- qi invasion regulation the powerless then hematogenous blockage of blood, the tired liver and gall of blood, the bile flowing outside the biliary passages and it is excessive, cause skin
Skin, icteric sclera.This is the card of asthenia in origin and asthenia in superficiality, controls and works as strengthening QI of middle-JIAO, makes the strong fortune of taste, and qi and blood biochemistry is active, and healthy tendency is sufficient, blood
Fortune is strong, and blood vessels are unimpeded；Invigorate blood circulation to change the power of tired walk help blood, cool blood is hot and suffocating to dissipate its, then bile can be followed often the tired elimination of liver and gall blood
Road and it is yellow from going.Therefore, treatment preferably rises clear with QI invigorating, based on promoting blood circulationization is tired.
Doctor trained in Western medicine thinks that the pathogenesis of chronic viral hepatitis type B is mainly due in Patients With Acute Viral Hepatitis body
Virus fail to be eliminated and body autoimmune disorders for a long time.Research confirmation, the morbidity of chronic viral hepatitis type B
Mechanism is relevant with the autoimmune response of liver plasma membrane composition (Guldottiet al., 1999), and autoimmunity is T cell regulation
Under humoral immunity it is not normal, be mainly shown as the appearance of anti-liver plasma membrane component antibodies, these antibody can coup injury liver cell
Also can mediate antibody dependence lymphocytotoxicity cause hepatocellular injury, and aggravate the damage of pathologic liver, chronic type b activity
The hepatocellular damage of property hepatitis and inflammatory reaction are due to the result that immunocyte is reacted hepatic tissue, wherein with cytotoxic T
Cytoclasis has viral liver cell mostly important.Cytotoxic T cell plays a significant role when the HBV in liver cell is removed,
It can recognize that there is the anti-liver cell of virus on surface, and liver cell is attacked under the synergy of macrophage and it is destroyed, while
Kill intracellular HBV (Webster et al., 2000).
But clinically there is no at present can the definite effectively specific medicament of fully erased virus B hepatitis virus.China
Chinese herbal medicine resource is enriched, and substantial amounts of experience is have accumulated in terms of hepatitis B is prevented and treated, and has also shown natural resources of Chinese medicinal materials advantage.
The content of the invention
1. pharmaceutical preparation of virus B hepatitis and preparation method thereof is treated it is an object of the invention to provide a kind of.
2. the Chinese medicine for the treatment of virus B hepatitis of the invention, is mainly made up of Chinese medicine material radix bupleuri.
3. the Chinese medicine of the invention described above, still further comprises addition pharmaceutic adjuvant and is made dosage form, the preparation choosing
Appoint from for powder, tablet, granule, capsule, microcapsules, pill, dripping pill, soft capsule, oral liquid, syrup, dispersible tablet etc.
Reasonable formulation on one pharmacy category；Auxiliary material used be selected from conventional solvent, disintegrant, flavouring, preservative, colouring agent,
Adhesive, lubricant, wetting agent, thickener, solubilizer.
4. in the present invention by Chinese medicine be used for treat virus B hepatitis, be with water, ethanol or carbon dioxide as solvent
The Chinese medicinal material extract of extraction, is prepared into the medicine suitable for clinically using.
5. preferred, Chinese medicinal material extract is extracted as solvent with water and is comprised the following steps：Chinese medicine is cut into 0.02~
2cm sections, weigh 60~110g, with 6~10 times amount water by medicinal material infiltrate 30~120min, decoct 1~3 time, 1~3 hour every time,
Filtration, merging filtrate, concentration, in temperature be 65~75 DEG C, vacuum be 0.08~0.1Mpa under conditions of drying under reduced pressure, i.e.,
.
6. comprised the following steps it is furthermore preferred that extracting Chinese medicinal material extract as solvent with water：Chinese medicine is cut into 1cm
Section, weighs 80g, and medicinal material is infiltrated into 30min with 8 times of amount water, decocts 2 times, 2 hours every time, filtration, merging filtrate, concentration, Yu Wen
Spend for 70 DEG C, vacuum are drying under reduced pressure under conditions of 0.1Mpa, obtain final product.
7. in preparation, take it is dialectical be combined with the differentiation of disease, the characteristics of according to traditional Chinese medical science Overall View considering dialectical treatmert, for
Acute hepatitis, chronic hepatitis, the traditional Chinese medicine interpretation of the cause, onset and process of an illness-jaundice of virus hepatitis, costalgia, liver pest, accumulation carry out selecting medicine prescription to form, Fang Zhong
Radix bupleuri has clearing heat and detoxicating, the effect of hepatic cholagogic.
8., in order to ensure effect of the invention, inventor has carried out a series of experiment to select the Chinese medicine of present invention offer
The extraction process of material extract, it is ensured that science, reasonable, feasible；Simultaneously in order to verify Chinese medicine in treatment virus B hepatitis
And its action effect in terms of complication, it is specific as follows applicant carried out series of experimental research：
Experimental example 1 extracts the selection of solvent and the roughing of extracting method
80 grams of the meal of Chinese medicine is taken, the scheme according to the form below 1 is tested, and result of the test is as shown in table 2：
The different extraction schemes of table 1
| Scheme one | Decoct and extract 2 times, 2 hours every time, amount of water was every time 10 times of medicinal material amounts |
| Scheme two | Refluxing extraction 2 times, 2 hours every time, plus 5% amount of alcohol is 10 times of medicinal material amounts |
| Scheme three | Refluxing extraction 2 times, 2 hours every time, plus 40% amount of alcohol is 10 times of medicinal material amounts |
| Scheme four | Refluxing extraction 2 times, 2 hours every time, plus 80% amount of alcohol is 10 times of medicinal material amounts |
| Scheme five | Refluxing extraction 2 times, 2 hours every time, plus 95% amount of alcohol is 10 times of medicinal material amounts |
| Scheme six | Supercritical CO2Bond quality makees entrainer, pressure 30MPa, 50 DEG C of extraction temperature, static immersing time 3h, dynamic extraction 3h than the ethanol for 5%； |
| Scheme seven | Supercritical CO2Bond quality makees entrainer, pressure 30MPa, 50 DEG C of extraction temperature, static immersing time 3h, dynamic extraction 3h than the ethanol for 40%； |
| Scheme eight | Supercritical CO2Bond quality makees entrainer, pressure 30MPa, 50 DEG C of extraction temperature, static immersing time 3h, dynamic extraction 3h than the ethanol for 75%； |
| Scheme nine | Supercritical CO2Bond quality makees entrainer, pressure 30MPa, 50 DEG C of extraction temperature, static immersing time 3h, dynamic extraction 3h than the ethanol for 95%； |
Influence of the different solvents of table 2 to paste-forming rate
As shown in Table 2：Chinese medicine is extracted by solvent of water and carbon dioxide, the paste-forming rate highest of extract, from saving into
This consideration, used as optimum extraction solvent, extracting mode selection is decocted extracts selection water.
The Chinese medicine extraction process by water of experimental example 2 is investigated
First, influence of the processing length of medicinal material to paste-forming rate
Chinese medicine 80g is weighed, medicinal material is infiltrated 30 minutes with 10 times of amount water, decocted 2 times, 2 hours every time, filtered, merging filtrate,
Concentration, carries out paste-forming rate measure, the results are shown in Table 3：
Influence of the medicinal material processing length of table 3 to paste-forming rate
From upper table 3：The paste-forming rate highest of medicinal material coarse powder, but liquid is difficult to filter after being extracted due to medicinal material coarse powder, tests
Although when can with machinery method drain the dregs of a decoction, be not particularly suited for big industrial production；And cut into 1.0cm sections of medicinal material
Paste-forming rate is close with the paste-forming rate of medicinal material coarse powder, therefore carries out extraction cutting into 1.0cm sections and be preferred.
2nd, influence of the soak time to paste-forming rate
Medicinal material water absorption rate is determined：Chinese medicine is processed into 1.0cm sections, 80g is weighed, immersion medicinal material is added water to completely, overnight, determined
Its water absorption rate, the results are shown in Table 4：
The soaked overnight medicinal material water absorption rate of table 4 is determined
| Packet | 1 | 2 | 3 | Average value |
| Water absorption rate（%） | 196 | 198 | 198 | 197.3 |
The Chinese medicine that 80g is processed into 1.0cm sections is weighed, medicinal material is infiltrated into different time with 10 times of amount water, decocted 2 times, 2 is small every time
When, filtration, merging filtrate, concentration determines paste-forming rate, the results are shown in Table 5：
The medicinal material of table 5 difference soak time
From upper table 5：Different soak times, it is little on the influence of the paste-forming rate of medicinal material, from the consideration that saves time and cost, with
Infiltration is preferred for 30 minutes.
3rd, the influence of different amount of water, decocting time and extraction time to paste-forming rate
After medicinal material processing length and soak time determine, according to preliminary experiment, the principal element to influenceing paste-forming rate is selected：Decoct
Time, extraction time and amount of water are boiled, using the method for orthogonal experiment, carries out investigating each with three varying levels of three factors
Influence of the link to paste-forming rate, so as to choose optimised process.Wherein factor level is as shown in table 6：
The overall merit experimental level of table 6
Using L9(34) orthogonal arrage tested, and 80 Chinese medicines for being processed into 1.0cm sections is weighed, by factor and level in table 6
Condition is carried out, and medicinal material soak time is 30 minutes, after extraction, extract solution filtration, and filtrate concentration carries out paste-forming rate measure, ties
Fruit is as shown in table 7：
The orthogonal arrage experimental result of table 7
As shown in Table 7：The order of each factor influence is A> B >Radix bupleuri, optimum extraction process is A2B2C2, i.e.,：It is processed into
1.0cm sections of Chinese medicine is extracted 2 times, and first time adds 8 times of amount water to soak 30 minutes, decocts 2 hours, and the decocting of 8 times of amounts is added for the second time
Boil 2 hours.
The extraction scheme of experimental example 3 is verified
According to the experimental condition for preferably going out, the Chinese medicine that 10000g is processed into 1.0cm sections is weighed, extracted 2 times, 8 times are added for the first time
Amount water soaks 30 minutes, decocts 2 hours, adds the decocting of 8 times of amounts to boil for the second time 2 hours, after extraction, extract solution filtration, filtrate concentration,
Drying under reduced pressure（Temperature is 65~75 DEG C, and vacuum is 0.08~0.1Mpa）Paste-forming rate measure is carried out, as a result as shown in table 8：
The extraction scheme of table 8 is verified
| Packet | 1 | 2 | 3 | Average value |
| Medicinal extract yield (%) | 24.4 | 24.3 | 24.4 | 24.4 |
From upper table 8, the experimental condition for preferably going out is reasonable, feasible for extracting Chinese medicine.
Paste-forming rate described in above-mentioned experimental example determine specific method be：Take and be concentrated into relative density 1.20~1.30（Survey
Determine temperature 60 C）Clear cream, be transferred in the volumetric flask of 1000ml and constant volume, shake up, precision measure 20ml be respectively placed in it is permanent
In the evaporating dish of weight, water-bath is volatilized, and residue took out in 105 DEG C of dryings 3 hours, is put and place 30 minutes in drier, is weighed, and is counted
Calculate；The extract water-bath of supercritical carbon dioxide extracting is volatilized, and is dried to constant weight at being placed in 105 DEG C, is weighed, and is calculated.
【Specific embodiment】The preparation of pharmacodynamics test and Chinese medicine preparation extract of the present invention
The present invention do not limited by following embodiments, can technology according to the present invention scheme and actual conditions determine specific reality
Apply mode.
【Specific embodiment】The extract pharmacodynamics test of Chinese medicine preparation of the present invention
1 material
1.1 experimental animals
Guangzhou sheldrake, purchased from Shi Jing Chaoyangs, Guangzhou hatchery.Weight is 90~105 during experiment.
Medicine and reagent
Chinese medicine of the present invention（Lot number：20150103）;Lamivudine:GlaxoSmithKline PLC pharmacy (Suzhou) Co., Ltd produces;
Digoxin DNA marker and detection kit, Roche Products;HBsAg ELISA detection kits, purchased from Shanghai Rong Sheng
Bioceuticals Inc.;ALT, AST kit, Bioengineering Research Institute is built up purchased from Nanjing.
Method
2.1 modelings and administration
Healthy 1 age in days Guangzhou sheldrake is taken, through the mL DHBV-DNA positive-virus serum of intraperitoneal inoculation 0.2, after 1 w of inoculation,
Blood is taken respectively at vena jugularis externa, is detected through dot hybridization with the DHBV-DNA probes of digoxigenin labeled and is filtered out the infection positive
Duck, raises
To 3 week old as animal pattern.The positive Guangzhou sheldrake of DHBV infection is randomly divided into 5 groups, i.e. model comparison
Group, lamivudine group and extract of the present invention it is low, in and high dose group, every group 12.Model group gavages physiological saline, rummy
Husband organizes according to dosage 50 mg/kg and gavages Lamivudine surely, and the basic, normal, high dosage group of extract of the present invention presses agent respectively
Amount 6.5,13.0,26.0 mg/kg gavages extract of the present invention.1 time/d, continuous 28 d.
Indexs measure
In 7 d after 7,14,28 d, drug withdrawal before administration, after administration, blood is taken from vena jugularis externa respectively, serum is separated, using spot
Hybrid method, is detected the serum before and after administration with the DHBV-DNA probes of digoxigenin labeled, with the plasmid homologous with probe
Point sample is standard in the spot colors depth for hybridizing display on cellulose nitrate film after DNA doubling dilutions, and film is carried out with scanner
Piece is scanned and carries out spot quantification, and by formula volume=intensity × mm2Spot value volume is calculated,
To reflect serum DHBV-DNA titre levels;Optical density D (λ) value is read by ELIASA using ELISA methods and detects blood
Clear HBsAg levels;To the serum of 7 d after 28 d of administration and drug withdrawal, while carrying out the inspection of ALT and AST activity according to kit
Survey.Additionally, in the dead each group animal in the 7th natural gift other places after drug withdrawal, taking hepatic tissue and being placed in 10% formalin fixed, paraffin
Dyeed with HE after section, carry out pathologic finding.
Statistical procedures
Experimental data represents that the statistical software for using is to compare to use One-Way between SPSS 16. 0, group with x ± s
ANOVA statistical dispositions.
As a result
Influence of 3.1 Chinese medicinal material extracts of the present invention to DHBV-DNA titres in duck serum
Result as shown in table 1, in after administration the 7th day, DHBV-DNA titres and mould in lamivudine group animal blood serum
Type control group compares, and significantly reduces (P ＜ 0.05 or P ＜ 0. 01), but the 7th day, DHBV-DNA titres in serum after drug withdrawal
Level raised.After administration 28d and be discontinued after the 7th day, in Chinese medicinal material extract low dose group animal blood serum of the present invention
DHBV-DNA titres compare equal significant difference (P ＜ 0. 05 or P ＜ 0.01) with model group;Opened in the 7th day after administration
Begin, the middle and high dosage group animal blood serum DH-BV-DNA titres of Chinese medicinal material extract of the present invention compare equal significant difference (P with model group
01), and the 7th day after drug withdrawal, the level of DHBV-DNA titres has no rising in serum for ＜ 0. 05 or P ＜ 0..
Influence (x ± s, n=12) of the Chinese medicinal material extract of the present invention of table 1 to DHBV-DNA titres in duck serum
Note:Compare with model group, * P<0.05, * * P<0.01
3. influence of 2 extracts of the present invention to duck HBsAg in serum
Result as shown in table 2, in after administration the 7th day, D (λ) values and model of lamivudine group animal blood serum HBsAg
Group comparing difference is notable (P ＜ 0.05 or P ＜ 0.01), but the 7th day after drug withdrawal, D (λ) value of HBsAg in serum has
Raised.The 28th day after administration, D (λ) value of HBsAg compares with model group in extract low dose group animal blood serum of the present invention
Significant difference (P ＜ 0. 05);In after administration the 1st day, in the middle and high dosage group animal blood serum of extract of the present invention
D (λ) values of HBsAg are notable (P ＜ 0.05 or P ＜ 0.01) with model group comparing difference, and the 7th day, serum after drug withdrawal
D (λ) value of middle HBsAg is without significantly raised.
Influence (x ± s, n=12) of the extract of the present invention of table 2 to duck HBsAg in serum
Note:Compare with model group, * P<0.05, * * P<0.01
3. influence of 3 extracts of the present invention to duck serum AST and ALT
Result as shown in table 3, after administration the 28th day and be discontinued after the 7th day, the work of lamivudine group animal blood serum AST and ALT
Property significantly raise (P ＜ 0. 01) compared with model group, but the 7th day after drug withdrawal, the 28th day after the activity of serum AST and ALT and administration
Compare, slightly rise.Upon administration the 28th day and be discontinued after the 7th day, the basic, normal, high dosage group animal blood serum of extract of the present invention
The activity of AST and ALT is significantly reduced (P ＜ 0.05 or P ＜ 0. 01) compared with model group, and the 7th day, serum after drug withdrawal
The activity of AST and ALT has no significantly raised.
The extract of the present invention of table 3 is to duck serum AST, the influence (x ± s, n=12) of ALT
Note:Compare with model group, * P<0.05, * * P<0.01
The influence that 3.4 extracts of the present invention change to hepatic tissue pathology
Hepatic tissue HE coloration results show:Model group lobuli hepatis structure is imperfect, and liver rope is disorderly, the enlargement of liver cell muddiness, change
Property, there are obvious inflammatory cell infiltration and liver cell point-like or focal necrosis phenomenon in portion of tissue portal area interlobular septum;Rummy husband
Surely group hepatic tissue structure is normal, and liver cell form shows no obvious abnormalities, and has no that obvious inflammatory cell infiltration and liver cell are bad
Dead phenomenon;Extract high dose group hepatic tissue structure of the present invention is normal, and hepatic sinusoid is clear, and cell has no without muddy enlargement
Obvious inflammatory cell infiltration and necrosis of liver cells phenomenon;The present invention extracts a small amount of slight hepatic cell muddiness enlargement of middle dosage thing group,
It can be seen that being dispersed in a small amount of point, the focal necrosis of distribution;Extract low dose group hepatic tissue structure of the present invention has small part abnormal,
And have a small amount of inflammatory cell infiltration and liver cell point-like or focal necrosis phenomenon.
Discuss
DHB and viruses of human hepatitis B belong to Hepadna Virus section together, at virus replication and the aspect such as pathogenic very
It is similar, therefore the experimental animal mould evaluated as research DHBV pathogenesis and hepatitis B virus resisting medicine using the duck of DHBV infection
Type is by domestic and foreign scholars
Generally acknowledge.This research uses duck hepatitis-B model, investigates the work of extract of the present invention anti-DHB in vivo
With as a result showing:Extract of the present invention can significantly reduce DHBV-DNA titres, HBsAg levels in hepatitis B model duck serum
And AST, ALT activity, and the 7th day after drug withdrawal, have no rebound phenomenon;Hepatic tissue HE dyeing at the 7th day after drug withdrawal
Result also shows:Extract of the present invention can reduce denaturation and necrosis and the inflammatory cell infiltration of liver cell.Prompting is the present invention extract
Thing has the effect of significant anti-DHB.
【Specific embodiment】The preparation of Chinese medicine preparation extract of the present invention
Embodiments of the invention 1：The preparation of Chinese medicinal material extract of the present invention：Chinese medicine of the present invention is cut into 1cm sections, is weighed
80g, 30min is infiltrated with 8 times of amount water by medicinal material, decocts 2 times, 2 hours every time, filtration, merging filtrate, concentration, in temperature be 70
DEG C, vacuum be 0.1Mpa under conditions of drying under reduced pressure, obtain final product.
Embodiment 2：The preparation of Chinese medicinal material extract of the present invention：Chinese medicine of the present invention is cut into 0.5cm sections, 90g is weighed,
Medicinal material is infiltrated into 60min with 7 times of amount water, 2 times are decocted, 2.5 hours every time, filtration, merging filtrate, concentration, in temperature be 68 DEG C,
Vacuum is drying under reduced pressure under conditions of 0.09Mpa, is obtained final product.
Embodiment 3：The preparation of Chinese medicinal material extract of the present invention：Chinese medicine of the present invention is cut into 2cm sections, 110g is weighed,
Medicinal material is infiltrated into 120min with 10 times of amount water, 3 times are decocted, 3 hours every time, filtration, merging filtrate, concentration, in temperature be 75 DEG C,
Vacuum is drying under reduced pressure under conditions of 0.1Mpa, is obtained final product.
Embodiment 4：The preparation of Chinese medicinal material extract of the present invention：Chinese medicine of the present invention is cut into 0.02cm sections, is weighed
80g, 30min is infiltrated with 6 times of amount water by medicinal material, is decocted 1 hour, filtration, concentration, in temperature be 65 DEG C, vacuum be 0.08Mpa
Under conditions of drying under reduced pressure, obtain final product.
Embodiment 5：The preparation of Chinese medicinal material extract of the present invention：Chinese medicine of the present invention is cut into 1cm sections, 100g is weighed,
Plus 5% alcohol refluxs of 10 times of medicinal material amounts extract 2 times, 2 hours every time, filtration, merging filtrate, concentration, in temperature be 72 DEG C, it is true
Reciprocal of duty cycle is drying under reduced pressure under conditions of 0.09Mpa, is obtained final product.
Embodiment 6：The preparation of Chinese medicinal material extract of the present invention：Chinese medicine of the present invention is cut into 1cm sections, 100g is weighed,
Plus 40% alcohol refluxs of 10 times of medicinal material amounts extract 2 times, 2 hours every time, filtration, merging filtrate, concentration, in temperature be 72 DEG C,
Vacuum is drying under reduced pressure under conditions of 0.09Mpa, is obtained final product.
Embodiment 7：The preparation of Chinese medicinal material extract of the present invention：Chinese medicine of the present invention is cut into 1cm sections, 100g is weighed,
Plus 80% alcohol refluxs of 10 times of medicinal material amounts extract 2 times, 2 hours every time, filtration, merging filtrate, concentration, in temperature be 72 DEG C,
Vacuum is drying under reduced pressure under conditions of 0.09Mpa, is obtained final product.
Embodiment 8：The preparation of Chinese medicinal material extract of the present invention：Chinese medicine of the present invention is cut into 1cm sections, 100g is weighed,
Plus 95% alcohol refluxs of 10 times of medicinal material amounts extract 2 times, 2 hours every time, filtration, merging filtrate, concentration, in temperature be 72 DEG C,
Vacuum is drying under reduced pressure under conditions of 0.09Mpa, is obtained final product.
Embodiment 9：The preparation of Chinese medicinal material extract of the present invention：Chinese medicine of the present invention is cut into 1cm sections, 100g is weighed,
CO2 means of supercritical extraction, wherein, entrainer is made with the ethanol that mass ratio is 5%, extracting pressure is 30Mpa, and extraction temperature is 50 DEG C,
The static immersing time is 3h, and dynamic extraction 3h, drying under reduced pressure is obtained final product.
Embodiment 10：The preparation of Chinese medicinal material extract of the present invention：Chinese medicine of the present invention is cut into 1cm sections, 100g is weighed,
CO2 means of supercritical extraction, wherein, entrainer is made with the ethanol that mass ratio is 40%, extracting pressure is 30Mpa, and extraction temperature is 50
DEG C, the static immersing time is 3h, and dynamic extraction 3h, drying under reduced pressure is obtained final product.
Embodiment 11：The preparation of Chinese medicinal material extract of the present invention：Chinese medicine of the present invention is cut into 1cm sections, 100g is weighed,
CO 2 supercritical is extracted, wherein, entrainer is made with the ethanol that mass ratio is 75%, extracting pressure is 30Mpa, extraction temperature
It it is 50 DEG C, the static immersing time is 3h, dynamic extraction 3h, drying under reduced pressure is obtained final product.
Embodiment 12：The preparation of Chinese medicinal material extract of the present invention：Chinese medicine of the present invention is cut into 1cm sections, 100g is weighed,
CO2 means of supercritical extraction, wherein, entrainer is made with the ethanol that mass ratio is 95%, extracting pressure is 30Mpa, and extraction temperature is 50
DEG C, the static immersing time is 3h, and dynamic extraction 3h, drying under reduced pressure is obtained final product.
Embodiment 13：The Chinese medicinal material extract of the present invention of any gained of Example 1 ~ 4, adds appropriate customary adjuvant,
Mix, drying, sterilizing, load hard shell capsules, packaging is made capsule..
Embodiment 14：The Chinese medicinal material extract of the present invention of any gained of Example 5 ~ 8, plus appropriate solubilizer, grinding,
Add a small amount of water to dilute, mix, add flavouring and preservative, mix, add water to ormal weight, filter, mix, packing, sterilizing,
It is made oral liquid.
Embodiment 15：The Chinese medicinal material extract of the present invention of any gained of Example 9 ~ 12, plus appropriate customary adjuvant, mix
It is even, particle is made, dry, compressing tablet is made tablet.
Embodiment 16：The Chinese medicinal material extract of the present invention of any gained of Example 1 ~ 4, adds conventional auxiliary material in right amount, into
Ball, dries, and is made pill.
Claims (9)
1. application of the radix bupleuri in the medicine for preparing treatment virus B hepatitis.
2. the application of Chinese medicine according to claim 1, prepares a kind of Chinese medicine for treating virus B hepatitis, mainly by
Chinese medicine radix bupleuri is made.
3. the application of Chinese medicine according to claim 1, prepares a kind of medicine for treating virus B hepatitis, mainly
It is made up of bupleurum extract, it is characterised in that：Radix bupleuri is extracted with water, ethanol or carbon dioxide as solvent and is made radix bupleuri extraction
Thing.
4. the application according to any one of claim 1 ~ 3, it is characterised in that：Described radix bupleuri is applied to preparation treatment second
The medicine of type virus hepatitis, is, with radix bupleuri as raw material, to be prepared into the medicine suitable for clinically using.
5. the application according to any one of claim 1 ~ 4, it is characterised in that：Described radix bupleuri is applied to preparation treatment second
The medicine of type virus hepatitis, is the compound medicine that radix bupleuri is made with the drug regimen for the treatment of virus B hepatitis.
6. the application of the Chinese medicine according to claim 1 ~ 5, it is characterised in that described medicine is powder, tablet, particle
On any pharmacy category such as agent, capsule, microcapsules, pill, dripping pill, soft capsule, oral liquid, syrup, dispersible tablet rationally
Formulation；Auxiliary material used is selected from conventional solvent, disintegrant, flavouring, preservative, colouring agent, adhesive, lubricant, moistening
Agent, thickener, solubilizer.
7. the application of the Chinese medicine according to claim 1 ~ 6, it is characterised in that be used to Chinese medicine treat B virus
Hepatitis, is the Chinese medicinal material extract extracted as solvent with water, ethanol or carbon dioxide, is prepared into the medicine suitable for clinically using
Thing.
8. the application of the Chinese medicine according to claim 1 ~ 7, it is characterised in that extract Chinese medicinal material extract by solvent of water
Comprise the following steps：Chinese medicine is cut into 0.02~1cm sections, 60~110g is weighed, medicinal material is infiltrated 35 with 8~11 times of amount water
~125min, decoct 2~3 times, 2~3 hours every time, filtration, merging filtrate, concentration, in temperature be 60~70 DEG C, vacuum be
Drying under reduced pressure under conditions of 0.08~0.1Mpa, obtains final product.
9. the application of the Chinese medicine according to claim 1 ~ 8, it is characterised in that extract Chinese medicinal material extract by solvent of water
Comprise the following steps：Chinese medicine is cut into 1cm sections, 80g is weighed, medicinal material is infiltrated into 30min with 8 times of amount water, decoct 2 times, often
Secondary 2 hours, filtration, merging filtrate, concentration, in temperature be 70 DEG C, vacuum be 0.1MPa under conditions of drying under reduced pressure, obtain final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201511007901.4A CN106924307A (en) | 2015-12-30 | 2015-12-30 | Application of the radix bupleuri in the medicine for preparing treatment virus B hepatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201511007901.4A CN106924307A (en) | 2015-12-30 | 2015-12-30 | Application of the radix bupleuri in the medicine for preparing treatment virus B hepatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106924307A true CN106924307A (en) | 2017-07-07 |
Family
ID=59459254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201511007901.4A Pending CN106924307A (en) | 2015-12-30 | 2015-12-30 | Application of the radix bupleuri in the medicine for preparing treatment virus B hepatitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106924307A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101342249A (en) * | 2008-08-29 | 2009-01-14 | 陕西东泰制药有限公司 | Chinese medicine formulations for treating hepatitis B and preparation method thereof |
| CN103224491A (en) * | 2013-05-22 | 2013-07-31 | 天津道谷生物科技有限公司 | Method for extracting high-purity puerarin by using water as solvent |
| CN104971190A (en) * | 2014-04-04 | 2015-10-14 | 张敏 | Application of dioscorea cirrhosa in preparation of medicines for preventing or treating diabetes and complications of diabetes |
-
2015
- 2015-12-30 CN CN201511007901.4A patent/CN106924307A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101342249A (en) * | 2008-08-29 | 2009-01-14 | 陕西东泰制药有限公司 | Chinese medicine formulations for treating hepatitis B and preparation method thereof |
| CN103224491A (en) * | 2013-05-22 | 2013-07-31 | 天津道谷生物科技有限公司 | Method for extracting high-purity puerarin by using water as solvent |
| CN104971190A (en) * | 2014-04-04 | 2015-10-14 | 张敏 | Application of dioscorea cirrhosa in preparation of medicines for preventing or treating diabetes and complications of diabetes |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101357219B (en) | Medicine for treating chronic hepatitis B | |
| CN105287940A (en) | Alcohol-dispelling beverage and preparation method thereof | |
| CN110787233B (en) | Liver-protecting traditional Chinese medicine composition, extract and pharmaceutical application thereof | |
| CN103301412A (en) | Traditional Chinese medicine composition for treating alcoholic liver | |
| CN104305205B (en) | A kind of Semen Cuscutae oral liquid improving immunity and preparation method thereof | |
| CN101829165B (en) | Method for preparing alcoholic liver disease medicinal tea by using Penthorum Chinense Pursh | |
| CN103301267B (en) | Traditional Chinese medicine composition for treating hypertension and/or atherosclerosis and application thereof | |
| CN106924340A (en) | Application of the Swertia mussotii in the medicine for preparing treatment virus B hepatitis | |
| CN103893593B (en) | Pharmaceutical composition with effects of clearing away heat and toxic materials, resisting inflammations and boosting immunity | |
| CN105106627A (en) | Medicinal preparation for treating diabetes | |
| CN106924307A (en) | Application of the radix bupleuri in the medicine for preparing treatment virus B hepatitis | |
| CN106924323A (en) | Application of the radix macrotomiae in the medicine for preparing treatment virus B hepatitis | |
| CN106924338A (en) | Application of the rough gentian in the medicine for preparing treatment virus B hepatitis | |
| CN106924313A (en) | Application of the witloof in the medicine for preparing treatment virus B hepatitis | |
| CN106924287A (en) | Application of the antelope's horn in the medicine for preparing treatment virus B hepatitis | |
| CN106924321A (en) | Application of the Artemisia japonica in the medicine for preparing treatment virus B hepatitis | |
| CN106924339A (en) | It is a kind of to treat Chinese medicinal formulae of virus B hepatitis and preparation method thereof | |
| CN101020016A (en) | Medicine for treating fracture and injured tendon and its prepn | |
| CN104622993B (en) | Chewable tablet with protective effect on alcoholic liver injuries and preparation method of chewable tablet | |
| CN112274586A (en) | Chinese herbal compound preparation for treating hepatic fibrosis and preparation method and application thereof | |
| CN1883582A (en) | Pharmaceutical composition for treating liver disease and method for preparing same | |
| CN104273527B (en) | A kind of health composition and its production and use | |
| CN104622987B (en) | A kind of pharmaceutical composition for treating chronic hepatitis liver cirrhosis and application | |
| CN103690771B (en) | Be used for the treatment of medicine of lamb colibacillosis and preparation method thereof | |
| CN103656446B (en) | Treat the compound Mongolian medicinal preparation and its preparation technology of coronary heart disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170707 |